We investigated whether Ukrain modulates the malignant phenotype of clear cell renal cell carcinoma (ccRCC) cells Caki-1, Caki-2, and ACHN treated with four doses (5, 10, 20, and 40 lmol/l) for 24 and 48 h. The epithelial-tomesenchymal transition markers E-cadherin, b-catenin, and vimentin were analyzed by immunofluorescence as well as actin and tubulin; matrix metalloproteinase-2 and matrix metalloproteinase-9 activity was analyzed by SDS-zymography, intracellular and secreted SPARC levels by western blot, and cell cycle by flow cytometry. Ukrain did not induce E-cadherin/b-catenin immunoreactivity at the cell-cell boundary, although it determined the actin cortical expression in Caki-2 and ACHN, and did not affect vimentin organization; however, in some Caki-1 and ACHN cells the perinuclear concentration of vimentin was consistent with its downregulation. Matrix metalloproteinase-2 and matrix metalloproteinase-9 activity was significantly downregulated 48 h after 20 lmol/l Ukrain administration. At this time point, Ukrain significantly decreased migration and invasion, and downregulated SPARC levels in cell supernatants at all doses in Caki-2, and at 20 lmol/l in Caki-1 and ACHN cells. Concomitantly, SPARC was upregulated in all ccRCC cells, suggesting that Ukrain could also affect cell proliferation by cell cycle inhibition, as supported by the cell cycle analysis, as SPARC also acts as a cell cycle inhibitor. Our results suggest that Ukrain may switch the epithelial-to-mesenchymal transition-related phenotype of ccRCC cells, and targets the two major aspects involved in RCC progression, such as tumor invasion/microenvironment remodeling and cell proliferation.
Introduction
Renal cell carcinoma (RCC) accounts for 80-85% of kidney tumors, among which 75% are the clear cell type (ccRCC), an aggressive and highly invasive RCC arising from the proximal convoluted tubules, characterized by a 20-30% recurrence after surgical resection and metastatic disease [1, 2] .
For most carcinomas, malignancy progression is accompanied by the phenotypic switch of differentiated renal tubular epithelial cells to mesenchymal cells, the socalled epithelial-to-mesenchymal transition (EMT) [3, 4] . In EMT, the loss of E-cadherin induces the disorganization of the adherens junctions and reduced cell-cell contacts between epithelial cells, largely contributing to the decreased cohesive architecture of normal epithelia. The de-novo expression of vimentin is a molecular marker frequently associated with EMT and the metastatic conversion of epithelial cells. Moreover, a correlation between vimentin expression and a perturbation of E-cadherin-mediated cell adhesion has been evidenced [5] . EMT plays a pivotal role rendering tumor cells invasive and metastatic [3, 4] . Phenotypic markers for EMT also comprise an increased capacity for migration and invasion accomplished by extracellular matrix (ECM) breakdown by matrix metalloproteinases (MMPs), leading to cancer cell dissemination and metastases [6] .
The anticancer drug Ukrain (NSC 631570) contains alkaloids of greater celandine (Chelidonium majus, a member of the Papaveraceae family) [7] and seems to have a potential effect in the treatment of a range of solid tumors including the colon, rectum, breast, pancreas, bladder, and ovary [8] [9] [10] [11] [12] [13] [14] .
However, the molecular mechanisms of Ukrain-induced antineoplastic effects are not yet completely understood, although an immunostimulating, immunomodulating [15] , and antiangiogenic action on human endothelial cells and a proapoptotic action on lymphoma and glioblastoma cells have been reported in vitro [16] [17] [18] [19] .
Here, we aimed at investigating whether Ukrain is able to modulate the expression of key markers of EMT and tumor progression in vitro, to assess its potential therapeutic effect.
Methods

Cell cultures
Three human ccRCC cell lines were used: Caki-1, Caki-2, and ACHN (American Type Culture Collection, Manassas, Virginia, USA). Cells were cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum, 2 mmol/l glutamine, antibiotics (100 U/ml penicillin, 0.1 mg/ml streptomycin), and 0.25 mg/ml amphotericin B.
Ukrain preparation and treatment
Ukrain (kindly provided by Nowicky Pharma, A-1040 Vienna, Austria) was obtained as a 5 mg water-soluble C. majus alkaloid thiophosphoric acid derivative in 5 ml of water. ccRCC cells were treated with four final concentrations of Ukrain (5, 10, 20 , and 40 mmol/l) for 24 and 48 h in serum-free medium. Untreated cultures served as controls. Each sample was cultured in duplicate.
Cell viability
Cell viability was determined by Trypan blue staining. Cells were plated in 6-well plates (300 000 cells/well) and allowed to attach. Fresh medium containing 5, 10, 20, and 40 mmol/l Ukrain was added, and cells were counted after 0, 24, 48, and 72 h.
Immunofluorescence
Cells were cultured on 12-mm-diameter round glass coverslips in 24-well culture plates. After 24 and 48 h, controls and Ukrain-treated cells were washed in phosphate buffered saline (PBS), fixed in 4% paraformaldehyde in PBS containing 2% sucrose for 5 min at room temperature (RT), postfixed in 70% ethanol, and stored at -201C until use. The cells were then washed in PBS three times and incubated for 1 h at RT with one of the following monoclonal antibodies: anti-E-cadherin (1 : 500, Becton Dickinson, Buccinasco-Milan, Italy), antivimentin (1 : 100, Novocastra Laboratories, Newcastle upon Tyne, UK), and anti-a-tubulin (1 : 2000, Sigma-Aldrich, Milan, Italy). Secondary antibody conjugated with Alexa 488 (1 : 500, Molecular Probes, Invitrogen, Paisley, UK) was applied for 1 h at RT in the dark. For b-catenin and b-actin analysis, cells were incubated for 1 h with the monoclonal antibody anti-b-catenin (1 : 100, Novocastra Laboratories) or anti-b-actin (1 : 1000, Sigma-Aldrich), respectively. Immunoreactivity was shown with the secondary antibody conjugated with tetramethyl rhodamine iso-thiocyanate (1 : 1000, Molecular Probes, Invitrogen) for 1 h at RT in the dark. In negative controls, the primary antibody was omitted. After the labeling procedure was completed, cells were incubated with 4',6-diamidino-2-phenylindole to stain nuclei (1 : 100 000, Sigma-Aldrich) for 15 min in the dark, and after washing in PBS the coverslips were mounted onto glass slides. The cells were photographed using a digital camera connected to the microscope (Nikon Eclipse E600, Nikon, Melville, New York, USA). Images were processed using specific software (Adobe Photoshop).
SDS-zymography
Culture media were mixed 3 : 1 with sample buffer (containing 10% SDS). Samples (15 mg of total proteins) were run under nonreducing conditions without heat denaturation on 10% polyacrylamide gel (SDS-polyacrylamide gel electrophoresis) copolymerized with 1 mg/ml of type I gelatin. The gels were run at 41C. After SDSpolyacrylamide gel electrophoresis, the gels were washed twice in 2.5% Triton X-100 for 30 min each and incubated overnight in a substrate buffer at 371C (Tris-HCl 50 mmol/l, CaCl 2 5 mmol/l, NaN 3 0.02%, pH 7.5). MMP gelatinolytic activity, detected after staining the gels with Coomassie Brilliant Blue R250 as clear bands on a blue background, was quantified by densitometric scanning (UVBand, Eppendorf, Milan, Italy).
Migration and invasion assay
Migration assay was performed using transwell inserts (6.5 mm insert diameter, 8 mm pore size) (Corning, New York, USA), placed in 24-well cell culture plates. In brief, 100 ml of a suspension with 1 Â 10 5 cell/ml in serum-free RPMI-1640 containing controls or Ukrain-treated cells was added to the top cell culture insert. RPMI-1640 containing 10% serum in the presence or absence of Ukrain at the same concentration of the insert was applied to the wells in which the top cell culture inserts containing cells were placed. Cell migration through the membrane was assessed by staining the cells that attached to the lower and the upper sides of the membrane with calcein-AM (3 mg/ml in PBS) for 30 min at 371C, 5% CO 2 . After staining, cells derived from the upper and the lower sides of the membrane were detached using trypsin, separately transferred into a clean tube, then centrifuged, lysed, and transferred to the black module strip. Fluorescence was measured at 485 nm (excitation) and 520 nm (emission). As a background, calcein-AM was incubated without cells. The number of migrating and nonmigrating cells was expressed as relative fluorescence units and the results were calculated as migration rate in relation to the total number of cells.
The invasive potential of controls and Ukrain-treated cells was assessed using the same transwell inserts coated with basement membrane matrix (Geltrex, Gibco, Paisley, UK) according to the manufacturer's instructions. The experimental procedures were the same as for the migration assay, and the number of cells able to invade through the matrigel and noninvading cells was calculated as invasion rate in relation to the total number of cells.
Each experimental point was run in duplicate, and data were expressed as the mean values ± standard deviation of three independent experiments.
Western blot
Cell lysates (40-60 mg) or culture media (15 mg of total proteins) were separated by 10% SDS-PAGE, and transferred at 90 V to a nitrocellulose membrane in 0.025 mol/l Tris, 192 mmol/l glycine, 20% methanol, pH 8.3. After electroblotting, the membranes were air dried and blocked for 1 h with 5% skim milk in Tris-buffered saline and Tween 20 and incubated for 1 h in monoclonal antibody to vimentin (1 : 1000, Novocastra Laboratories). To confirm equal loading, membranes were reprobed by monoclonal antibody to a-tubulin (1 : 2000 dilution, Sigma-Aldrich).
For secreted protein acidic and rich in cysteine (SPARC) analysis, membranes were incubated for 1 h at RT in monoclonal antibody to SPARC (1 : 100 in Tris-buffered saline and Tween 20, Novocastra Laboratories), and after washing, in horseradish peroxidase-conjugated rabbit antimouse serum (1 : 6000 dilution, Sigma-Aldrich). Immunoreactive bands, shown using the Opti-4CN substrate (Bio Rad, Segrate-Milan, Italy), were scanned densitometrically (UVBand, Eppendorf).
Cell cycle analysis
The cell phase distribution 48 h after Ukrain treatment was assayed by determination of the DNA content as previously described [20] . Cells were trypsinized (trypsin 0.025%; EDTA 0.01% in PBS), fixed in 70% ethanol at -201C, treated with 100 mg/ml RNase A for 30 min at 371C, stained with 1 ml of a solution containing propidium iodide (50 mg/ml) in PBS and RNase A (100 mg/ml), and maintained at 41C for at least 12 h. Monoparametric cell cycle analysis was performed on at least 2 Â 10 4 cells for each sample using an FacsCanto II instrument equipped with FacsDiva 6.1 Software (Becton Dickinson) and the distribution of the different cell cycle phases was calculated.
Annexin V
The apoptosis ratio in controls and Ukrain-treated cells was analyzed at the time points of 24 and 48 h using the Annexin V-FITC Apoptosis Detection Kit (Calbiochem, Nottingham, UK) according to the manufacturer's instructions.
Statistical analysis
Data, expressed by mean ± standard deviation, were analyzed by one-way analysis of variance and the Student-Neumann-Keuls post hoc test (Prism GraphPad). P values of less than 0.05 were considered significant.
Results
Cell viability and proliferation
Ukrain administration dose-dependently decreased cell proliferation in all three cell lines (Fig. 1) . Inhibition of cell proliferation was evident 24 h after 10, 20, and 40 mmol/l Ukrain administration, and 48 h after all doses of Ukrain. The administration of 40 mmol/l Ukrain induced the death of all ACHN cells 48 h after treatment. Therefore, we investigated whether the drug was effective in inducing apoptosis by analyzing annexin V expression. Our results point to a dose-dependent increase of the number of apoptotic cells after both the 24 and the 48 h time points (Fig. 2) . Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Cell morphology
Cell morphology was similarly affected by Ukrain administration after 24 (data not shown) and 48 h (Fig. 3) . Morphological changes occurred in Caki-1 and ACHN cells after Ukrain administration. Untreated Caki-1 and ACHN grew as loosely adherent spindle-shaped, fibroblast-like cells suggestive of a mesenchymal phenotype. After Ukrain administration, they tended to grow as fairly tight aggregates, in which cells showed a rounded polygonal shape consistent with a more epithelial-like phenotype. By contrast, Caki-2 cells are small polygonal growing cells forming small aggregates whose appearance is not modified after Ukrain administration. Figure 3 shows that 48 h after administration of 40 mmol/l Ukrain, the most part of Caki-1 and Caki-2 cells are dead, while at this time point Ukrain killed all ACHN cells. As a consequence, all the immunofluorescence and molecular evaluations at the 48 h time point were performed on cells after Ukrain 5, 10, and 20 mmol/l administration.
Immunofluorescence analysis for tubulin showed that microtubule cytoskeleton remained preserved in all controls and Ukrain-treated cells (Fig. 4) .
Epithelial-to-mesenchymal transition markers
E-cadherin is a transmembrane glycoprotein whose cytoplasmic domain is complexed with b-catenin. When during EMT the loss or cleavage of E-cadherin occurs, b-catenin internalization is promoted. We analyzed E-cadherin and b-catenin expression and localization in ccRCC cells. Their pattern of expression was very similar to both 24 and 48 h after Ukrain administration. In Caki-2 cells (Fig. 5) , both E-cadherin and b-catenin immunoreactivity were similarly expressed in the cytoplasm of controls and Ukrain-treated cells. Hence, Ukrain seems to be unable to induce junctional localization of these proteins to the cell-cell contact sites as in normally differentiated epithelial cells. A similar pattern was observed for Caki-1 and ACHN (Fig. 5 ).
In all controls, a diffuse pattern consisting of actin stress fibers was evident ( Fig. 6 ). Ukrain administration did not affect actin filament arrangement in Caki-1. In contrast, in Caki-2 and ACHN cells, Ukrain induced actin expression at the boundary between cells starting after 5 mmol/l and 10 mmol/l Ukrain, respectively, suggesting that Ukrain administration elicits actin cytoskeleton reorganization in ccRCC cells. This effect was observed in some ACHN cells 24 h after 20 and 40 mmol/l Ukrain administration (data not shown).
The majority of the cells showed vimentin dispersed filaments, typical of the vimentin network ( Fig. 7 ). Both in controls and Ukrain-treated cells, vimentin filaments were found around the nucleus, from which they irradiated out into the cell periphery in fine lace-like threads (see the representative box in Fig. 7 ), suggesting that Ukrain does not affect the vimentin organization, typical of mesenchymal cells. Western blot analysis confirmed that vimentin expression is not quantitatively affected by Ukrain (Fig. 8) . However, few Caki-1 and ACHN cells starting after 5 mmol/l Ukrain administration showed a perinuclear concentration of vimentin immunoreactivity with only limited filamentous extension, consistent with a downregulation of the protein [21] ( Fig. 7, arrows) . Hence, although in some cells vimentin seems downregulated by Ukrain, western blot analysis shows that Ukrain is not able to decrease the overall vimentin expression in Caki-1 and ACHN cells. In Caki-2 cells, vimentin expression slightly tended to increase 48 h after 10 and 20 mmol/l Ukrain administration, but this pattern is not statistically significant.
Matrix metalloproteinase activity
MMP activity was analyzed by SDS-zymography. Densitomentric analysis of the zymograms showing MMP-2 and MMP-9 activity 24 h after Ukrain treatment shows that at this time point supernatants of controls and Ukraintreated cells have the same gelatinase activity (Fig. 9b) . Forty-eight hours after Ukrain administration, MMP-2 activity ( Fig. 9a and b) in cell supernatants strongly decreased after Ukrain 20 mmol/l in Caki-1 (P < 0.0005 for Ukrain 20 mmol/l vs. 10 mmol/l, P < 0.005 for Ukrain 20 mmol/l vs. controls and 5 mmol/l), in Caki-2 (P < 0.005 for Ukrain 20 mmol/l vs. controls and 10 mmol/l), and ACHN (P < 0.005 for Ukrain 20 mmol/l vs. controls). MMP-9 activity was significantly downregulated by Ukrain in Caki-1 (P < 0.0005 for Ukrain 20 mmol/l vs. 10 mmol/l, P < 0.005 for Ukrain 20 mmol/l vs. controls 5 mmol/l), and tended to drop after Ukrain 20 mmol/l administration in Caki-2 and ACHN cells (P not significant).
Migration and invasion assay
As differences in MMPs activity between controls and Ukrain-treated samples were not found 24 h after Ukrain administration, the functional migration and invasion assays were performed on samples treated for 48 h. The migration rate (Fig. 10a) was strongly reduced by Ukrain in Caki-1 (P < 0.05 for Ukrain 5 and 20 mmol/l vs. controls), Caki-2 (P < 0.0005 for Ukrain 20 mmol/l vs. controls, 5 and 10 mmol/l, P < 0.05 for controls vs. Ukrain 5 and 10 mmol/l), and ACHN cells (P < 0.005 for Ukrain 10 and 20 vs. 5 mmol/l).
Ukrain also induced a significant decrease of the percentage of invading cells (Fig. 10b ) (for Caki-1, Caki-2, and ACHN P < 0.005 for Ukrain 10 and 20 mmol/l vs. controls; for Caki-1 and Caki-2 P < 0.05 for Ukrain 5 mmol/l vs. controls).
Secreted protein acidic and rich in cysteine expression SPARC expression was analyzed both in cell culture supernatants and at the intracellular level. Twenty-four Caki-1, was significantly increased after Ukrain 20 mmol/l in Caki-2 compared with controls (P < 0.05), and resulted unchanged in ACHN cells, although in this cell line Ukrain induced a significant increase of SPARC 24 h after 20 and 40 mmol/l Ukrain administration (Fig. 11a) .
In contrast, SPARC protein levels in cell supernatants showed an opposite pattern of expression 48 h after Ukrain administration. In fact, SPARC protein levels strongly decreased in Caki-1 after 20 mmol/l Ukrain administration (P < 0.005 for Ukrain 20 mmol/l vs. controls; P < 0.05 for Ukrain 20 vs. 10 and 5 mmol/l), in Caki-2 (P < 0.0005 for Ukrain 5 and 10 mmol/l vs. controls, P < 0.005 for Ukrain 20 mmol/l vs. controls), and in ACHN (P < 0.05 for Ukrain 20 mmol/l vs. controls, P < 0.005 for Ukrain 20 mmol/l vs. Ukrain 5 and 10 mmol/l) (Fig. 11b) .
Cell cycle analysis
Flow cytometry analysis of the DNA content showed a G2/M phase cell cycle arrest after Ukrain treatment ( Table 1 ). The percentage of cells in G2/M increased 48 h after Ukrain administration, and this effect was evident after Ukrain 20 mmol/l treatment. These results indicate that Ukrain primarily induced G2/M phase arrest in ccRCC cancer cells. 
Discussion
Progression of carcinomas is accompanied by EMT, leading to the loss of epithelial characteristics and the acquisition of a mesenchymal phenotype that play a pivotal role rendering tumor cells invasive and able to disseminate forming metastasis.
We investigated in vitro whether Ukrain affects ccRCC cell proliferation and the expression of EMT markers and of genes and proteins involved in the mechanisms leading to tumor invasion. Ukrain dose-dependently reduced ccRCC cell proliferation 24, 48, and 72 h after treatment.
This was evident after the 10 mmol/l dose and suggests that the drug has a cytostatic effect possibly elicited, according to previous findings, by inhibition of DNA, RNA, and protein synthesis, and by the induction of apoptosis [16, 17, 19, 22] . This last hypothesis was supported by the analysis of annexin V expression, showing a dosedependent increase of the percentage of apoptotic cells in Ukrain-treated ccRCC cells compared with controls.
It was previously shown that UK decreased cell proliferation and increased the blocking of cells in G2/M because of the depolymerization of tubulin [23] and the (b) Bar graphs showing proMMP-2 and proMMP-9 activity in Caki-1, Caki-2, and ACHN serum-free conditioned media after densitometric analysis of lytic bands following SDS-zymography. Our results show that Ukrain significantly affects MMP-2 and MMP-9 activity, suggesting that this drug may elicit a relevant effect on the mechanisms responsible for tumor invasion. Data are expressed as densitometric units ± standard deviation for three independent experiments for samples run in duplicate. *P < 0.0005 vs. 10 mmol/l; **P < 0.005 vs. CT and 5 mmol/l;^P < 0.005 vs. CT and 10 mmol/l; and 1P < 0.005 vs. CT.
Ukrain and renal cell carcinoma Gagliano et al. 757 consequent 'mitotic slippage'. Our data are discordant as the immunofluorescence analysis showed a wellconserved tubulin cytoskeleton, clearly evident astral microtubules, and the absence of abnormal mitosis, thus suggesting that the antimitotic and the antiproliferative effect of Ukrain is not based on tubulin cytoskeleton alteration.
Cell morphology and epithelial-to-mesenchymal transition
Loss of intercellular adhesion and increased motility promote tumor cell invasion. Acquisition of metastatic phenotype consists of multiple steps, including EMT, which is a complex step-wise process in which the loss of epithelial adhesion, the disruption of basement membrane, and the enhanced migration and invasion are necessary for the completion of the entire mechanism [24] . The loss of cell-cell adhesion is a hallmark of EMT that allows tumor cells to acquire the ability to infiltrate surrounding tissue and metastasize [6] . The graded loss of E-cadherin, the core transmembrane protein of the adherens junctions of differentiated and polarized epithelial cells, correlates with the aggressiveness of numerous carcinomas and the worsening of prognosis, whereas the forced expression of E-cadherin suppresses tumor development in various in-vitro and in-vivo tumor experimental models [25] . Moreover, adherens junctions were dramatically reduced in patients with ccRCC compared with normal tissues [26] .
E-cadherin binds catenin that connects the cadherin complex to the actin cytoskeleton. Release of the E-cadherin/b-catenin complex from the membrane has been previously reported to induce cell-cell junction elimination [27] and b-catenin nuclear translocation, in which it may function as a transcriptional coactivator [28] .
Our data show that both E-cadherin and b-catenin localization is cytoplasmic in controls ccRCC cells, in contrast with the typical protein localization in the cellular borders and contact sites of differentiated epithelial cells, and that Ukrain is not able to affect their overall expression, or to induce their reexpression at the plasma membrane level, suggesting that Ukrain is not able to modulate these EMT-related phenotype markers at both the considered time points.
We investigated the actin cytoskeleton because changes in the arrangement of actin filaments are common features in cellular transformation [29] . In particular, during EMT dramatic cytoskeleton reorganization occurs, and actin subcortical mesh in epithelial cells is dissociated [30] . We observed diffuse actin stress fibers in controls ccRCC cells. This pattern is not affected by Ukrain in Caki-1 cells. Interestingly, in Caki-2 and ACHN Ukrain administration induced evident actin localization at the cell-cell contacts, suggesting that Ukrain administration may elicit a reorganization of the actin cytoskeleton and the formation of cortical filament bundles, typical of the epithelial phenotype. As in transformed Vimentin is a widely used marker of EMT. Silencing vimentin causes mesenchymal cells to adopt epithelial shapes, and following transfection with vimentin cDNA epithelial cells adopt mesenchymal shapes coincident with vimentin intermediate filaments assembly. The induction of EMT in Madin-Darby canine kidney cells is characterized by decreased E-cadherin expression, by increased vimentin expression [32] , and by increased cell motility [33] . Several studies have shown that vimentin upregulation in carcinomas correlates with parameters of malignancy such as tumor grade and survival incidence [34] , and RCC is reported to constantly express vimentin 
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Bar graphs showing secreted protein acidic and rich in cysteine (SPARC) protein levels in cell lysates (a) and secreted in cell supernatants (b). Data were obtained after densitometric scanning of immunoreactive bands and are expressed as densitometric units. This pattern of SPARC protein levels suggests that 48 h after administration Ukrain is able to concomitantly and specifically target extracellular and intracellular SPARC, reducing extracellular matrix remodeling in the tumor environment and possibly reducing cell proliferation. Data were obtained from three independent experiments for samples run in duplicate and are expressed as densitometric units ± standard deviation. } P < 0.05 vs. control (CT) and 10 and 5 mmol/l, *P < 0.005 vs. CT; **P < 0.05 vs. 10 and 5 mmol/l;^P < 0.0005 vs. CT; 1P < 0.05 vs. CT; and 11P < 0.005 vs. 10 and 5 mmol/l. To further discuss these data on EMT markers and cell morphology, we can provide a further consideration, on the basis of the evidence that it was shown that invasive and metastatic epithelial cells show a well-differentiated phenotype characterized by the expression of E-cadherin [36] . This can be explained as an incomplete EMT, thereby suggesting that the transition to an aggressive malignant phenotype is not an 'all or nothing' event, but rather a multistep process that manifests in a broad range of phenotypic changes [37] . Moreover, the steps characterizing the EMT multistep process do not necessarily occur consecutively and are not all necessarily present in a given sample of EMT. On the basis of these suggestions, we can hypothesize that Ukrain may revert the malignant phenotype of ccRCC cells by modification of the actin and vimentin cytoskeleton leading to a more epitheliallike polarized phenotype, although in these cells the pattern of expression of E-cadherin/b-catenin complex is not affected.
Matrix metalloproteinases activity and invasive potential
Disturbances of the finely tuned homeostasis of ECM may have significant roles in many diseases, such as fibrosis, and in tumor progression [38] . The physical processes of tumor invasion, which involves disengagement of the cells from their microenvironment, followed by breakdown of the surrounding ECM, cell movement, and reestablishment of the local environment at a new site, enable cancer cells at the tumor-invasive front to overcome the ECM barrier, and penetrate adjacent tissues. This is accomplished by an ECM remodeling process involving MMPs and SPARC [39] .
MMPs are key markers of EMT, and in-vitro studies showed that ECM remodeling and proteolytic degradation of ECM by MMPs are major steps in tumor invasion [40] , leading to cancer cell dissemination and metastases. We aimed at analyzing whether Ukrain is able to affect the expression of the gelatinases MMP-2 and MMP-9, playing a relevant role during tumor invasion, because of their activity in degrading type IV collagen of basement membranes [41] .
In RCC, upregulation of the MMP-2 and MMP-9 proteins correlates with poor prognostic variables [42] . Patients with ccRCC with high MMP-2 activation ratio or high MMP-9 had a significantly worse outcome [43] , and poor survival with high frequency of metastases is associated with MMP-9 activity [44, 45] . However, both MMP-2 and MMP-9 seem engaged in the promotion and progression of RCC [42] .
In particular, patients with RCC with involvement of major veins or invasion to perinephric tissues had higher expression of active MMP-2 than those whose tumors were limited to the kidneys [43] . This supports the key role of MMPs in tumor invasion and metastasis. Interestingly, a tendency to higher expression and activation of MMP-2 was described in T3 tumors, compared with T1 and T2, leading to the hypothesis that MMP-2 may play a key role in initiating RCC metastasis [43] .
The overall pattern of protein expression of MMP-2 and MMP-9 shows that Ukrain is able to significantly decrease their activity 48 h after administration, suggesting that Ukrain could modulate the invasive potential of ccRCC cells. This suggestion was strongly confirmed by the invasion assay on matrigel, showing that Ukrain-treated cells show a less invasive potential.
Secreted protein acidic and rich in cysteine protein expression
Tumor invasion and metastasis occur in the context of the ECM, and the cellular interactions with ECM are mediated by SPARC, a matricellular glycoprotein involved in several biological processes involving ECM remodeling [46, 47] . SPARC is highly expressed in a wide range of human malignant tumors, and its deregulated expression is often correlated with disease progression and/or poor prognosis [48] [49] [50] [51] [52] [53] . Although SPARC is generally overexpressed in malignant tumors, it was shown that SPARC has a tumor-suppressor function in ovarian cancer cells [54] . Thus, the biological properties of SPARC may be variable among different cancer types.
SPARC shows de-adhesive properties through an antagonistic action involving integrin signaling [55] , allowing the regulation of cell-matrix interactions. In the mechanisms leading to tumor invasion, the ability of the tumor cell to migrate and invade the surrounding environment is dependent on the modulation of the interactions between tumor cells and ECM components. Therefore, SPARC may have a functional role during tumor cell invasion into adjacent tissues.
Our results show that the secreted SPARC protein levels are significantly downregulated by Ukrain in the supernatants of all the considered cell lines, suggesting that Ukrain may be effective to reduce the ECM remodeling, thus rendering the tumor microenvironment less permissive to tumor invasion and migration.
SPARC expression in cell lysates has an opposite pattern of expression compared with the secreted protein.
In fact, our results show that SPARC intracellular protein levels, although unchanged in ACHN after Ukrain treatment, were increased in Caki-1 and Caki-2 48 h after Ukrain administration. This is a very interesting finding, as SPARC is also a potent antiproliferative agent because of its ability to inhibit the cell cycle [56] . Intracellular SPARC downregulation, because of the methylation of its promoter, was previously described in human ovarian cancer [57, 58] , and was related to increased proliferation and cell cycle progression [56] . Therefore, high levels of intracellular SPARC induced by Ukrain administration may be related to a reduced ability of cells to enter the cell cycle, and as a consequence, to a reduced cell proliferation [59] .
Our data on intracellular SPARC levels are consistent with the cell cycle analysis showing that a considerable number of Ukrain-treated cells were arrested in the G2/M phase, and provide strong evidence that Ukrain may contribute to induce cell cycle arrest, and in turn the inhibition of cell division in ccRCC cells. However, further studies are needed to weight a possible link between SPARC intracellular levels and reduced cell proliferation after Ukrain administration.
The overall SPARC expression suggests that Ukrain is able to target extracellular and intracellular SPARC, reducing ECM remodeling in the tumor environment and possibly reducing cell proliferation. This hypothesis is based on the suggestion that SPARC may elicit different effects extracellularly and intracellularly, according to the finding that SPARC may be translocated into the nucleus after endocytosis [60] , where the protein may exert its effects on cell cycle. However, the complex mechanisms leading to concomitantly different intracellular and secreted SPARC levels remain an open question.
Conclusion
Considered as a whole, our results suggest that Ukrain may exert relevant effects on ccRCC progression. In particular, we show that Ukrain targets some EMT markers in ccRCC cells leading to the acquisition of an epithelial-like phenotype induced by Ukrain administration, and strongly affects two major aspects involved in RCC tumorigenesis, which are ECM remodeling and cell proliferation.
